GGrantIndex
← Leaderboards

Bruce R Schackman

Weill Medical College Of Cornell Univ

Google Scholar ↗PubMed ↗ORCID ↗
$21,876,043
Attributed
$28,025,451
Total exposure
12
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$44,351,741 · 13

By mechanism

P30$24,850,687 · 6
R01$8,545,280 · 3
U24$6,550,146 · 1
U01$3,491,173 · 1
K01$840,340 · 1
R13$74,115 · 1

Top collaborators

Others in their field

Top investigators on “Research Personnel”

Research focus

Research PersonnelEconomicsPoliciesCaringServicesHepatitis C VirusInnovationResourcesMethodologyCommunitiesHiv/HcvSubstance Use DisorderEconomic EvaluationProgramsPolicy MakerHealth EconomicsFundingHealthcareCostHepatitis CGrantPharmaceutical PreparationsModels And SimulationEnsure

Grant awards (71)

Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation$2,270,589
P30 · FY2025 · DA · contact PI
HEAL Data2Action Modeling and Economic Resource Center$1,562,051
U24 · FY2025 · DA · contact PI
Administrative Core$752,488
P30 · FY2025 · DA · contact PI
HEAL Data2Action Modeling and Economic Resource Center$1,599,903
U24 · FY2024 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Evaluating Intervention Outcomes for Individuals, Systems, and Communities$1,564,216
P30 · FY2024 · DA · contact PI
Core 1: Administrative Core$596,293
P30 · FY2024 · DA · contact PI
Core 3: Population & Data Modeling$379,197
P30 · FY2024 · DA · contact PI
HEAL Data2Action Modeling and Economic Resource Center$1,632,231
U24 · FY2023 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Evaluating Intervention Outcomes for Individuals, Systems, and Communities$1,589,988
P30 · FY2023 · DA · contact PI
DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)$666,952
U01 · FY2023 · DA · contact PI
Core 1: Administrative Core$614,325
P30 · FY2023 · DA · contact PI
Core 3: Population & Data Modeling$379,570
P30 · FY2023 · DA · contact PI
Simulation Modeling to Support the Public Health Response to the Opioid Crisis in North America$24,409
R13 · FY2023 · DA · contact PI
HEAL Data2Action Modeling and Economic Resource Center$1,755,961
U24 · FY2022 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Evaluating Intervention Outcomes for Individuals, Systems, and Communities$1,564,216
P30 · FY2022 · DA · contact PI
DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)$675,102
U01 · FY2022 · DA · contact PI
Core 1: Administrative Core$596,293
P30 · FY2022 · DA · contact PI
Core 3: Population & Data Modeling$379,197
P30 · FY2022 · DA · contact PI
Simulation Modeling to Support the Public Health Response to the Opioid Crisis in North America$24,708
R13 · FY2022 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Evaluating Intervention Outcomes for Individuals, Systems, and Communities$1,611,681
P30 · FY2021 · DA · contact PI
DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs$790,403
R01 · FY2021 · DA · contact PI
DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)$683,778
U01 · FY2021 · DA · contact PI
Core 1: Administrative Core$613,316
P30 · FY2021 · DA · contact PI
Core 3: Population & Data Modeling$381,154
P30 · FY2021 · DA · contact PI
Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorder$89,950
P30 · FY2021 · DA · contact PI
Simulation Modeling to Support the Public Health Response to the Opioid Crisis in North America$24,998
R13 · FY2021 · DA · contact PI
DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs$9,831
R01 · FY2021 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Evaluating Intervention Outcomes for Individuals, Systems, and Communities$1,647,530
P30 · FY2020 · DA · contact PI
DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)$694,128
U01 · FY2020 · DA · contact PI
Core 1: Administrative Core$608,589
P30 · FY2020 · DA · contact PI
DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs$606,428
R01 · FY2020 · DA · contact PI
Core 3: Population & Data Modeling$411,349
P30 · FY2020 · DA · contact PI
DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs$179,194
R01 · FY2020 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care$1,146,565
P30 · FY2019 · DA · contact PI
DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)$771,213
U01 · FY2019 · DA · contact PI
DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs$689,437
R01 · FY2019 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (Admin Core)$313,116
P30 · FY2019 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (Methodology Core)$311,414
P30 · FY2019 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care$98,767
P30 · FY2019 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care$1,153,905
P30 · FY2018 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (Methodology Core)$318,183
P30 · FY2018 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (Admin Core)$298,199
P30 · FY2018 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care$1,153,333
P30 · FY2017 · DA · contact PI
Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs$485,246
R01 · FY2017 · DA · contact PI
Economic Evaluation of Medication-Assisted Substance Abuse Treatment$402,058
R01 · FY2017 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (Admin Core)$341,346
P30 · FY2017 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (Methodology Core)$264,051
P30 · FY2017 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care$99,998
P30 · FY2017 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care$1,127,032
P30 · FY2016 · DA · contact PI
Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs$485,416
R01 · FY2016 · DA · contact PI
Economic Evaluation of Medication-Assisted Substance Abuse Treatment$386,697
R01 · FY2016 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (Methodology Core)$257,211
P30 · FY2016 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (Admin Core)$225,696
P30 · FY2016 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care$1,208,520
P30 · FY2015 · DA · contact PI
Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs$522,235
R01 · FY2015 · DA · contact PI
Economic Evaluation of Medication-Assisted Substance Abuse Treatment$399,743
R01 · FY2015 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (Admin Core)$241,705
P30 · FY2015 · DA · contact PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (Methodology Core)$241,705
P30 · FY2015 · DA · contact PI
Quality of life outcomes in prescription and injection opioid dependence$588,560
R01 · FY2014 · DA · contact PI
Economic Evaluation of Medication-Assisted Substance Abuse Treatment$442,054
R01 · FY2014 · DA · contact PI
Quality of Life Outcomes in Prescription and Injection Opioid Dependence$10,871
R01 · FY2014 · DA · contact PI
Quality of life outcomes in prescription and injection opioid dependence$469,792
R01 · FY2013 · DA · contact PI
Quality of life outcomes in prescription and injection opioid dependence$539,174
R01 · FY2012 · DA · contact PI
Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs$498,584
R01 · FY2011 · DA · contact PI
Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs$505,859
R01 · FY2010 · DA · contact PI
Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs$533,698
R01 · FY2009 · DA · contact PI
HCV Treatment Cost-Effectiveness in 3 IDU Populations$169,492
K01 · FY2008 · DA · contact PI
HCV Treatment Cost-Effectiveness in 3 IDU Populations$168,179
K01 · FY2007 · DA · contact PI
HCV Treatment Cost-Effectiveness in 3 IDU Populations$178,091
K01 · FY2006 · DA · contact PI
HCV Treatment Cost-Effectiveness in 3 IDU Populations$173,830
K01 · FY2005 · DA
HCV Treatment Cost-Effectiveness in 3 IDU Populations$150,748
K01 · FY2004 · DA